Market news

SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address...

The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Record physician engagement and broad-based demand drive 15% revenue growth.

The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Moby summary of SI-BONE, Inc.'s Q2 2026 earnings call

SI-BONE Inc (SIBN) delivers 15% revenue growth, narrows net loss, and raises full-year guidance on robust procedure volume and promising reimbursement tailwinds.

Si-Bone (SIBN) delivered earnings and revenue surprises of +40.00% and +1.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

SiBone (NASDAQ:SIBN) reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio. Worldwide revenue reached $56 million for the quarter ended June 30, while U.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.0 million, representing growth of 15.2%U.S. revenue of $53.2 million, representing growth of 14.7%Gross margin of 79.5%Net loss of $4.1 million, representing an improvement of 33.6%Positive adjusted EBITDA of $2.8 million, an improvement of 178.0%Positive cash from operations of

SI-BONE (SIBN) has an average rating of buy and mean price target of $24.50, according to analysts p

SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by r

SI-BONE (SIBN) has an average rating of buy and mean price target of $24.50, according to analysts p